288 related articles for article (PubMed ID: 31898971)
21. Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation.
Tokunaga F; Nishimasu H; Ishitani R; Goto E; Noguchi T; Mio K; Kamei K; Ma A; Iwai K; Nureki O
EMBO J; 2012 Oct; 31(19):3856-70. PubMed ID: 23032187
[TBL] [Abstract][Full Text] [Related]
22. Cooperative inhibition of RIP1-mediated NF-κB signaling by cytomegalovirus-encoded deubiquitinase and inactive homolog of cellular ribonucleotide reductase large subunit.
Kwon KM; Oh SE; Kim YE; Han TH; Ahn JH
PLoS Pathog; 2017 Jun; 13(6):e1006423. PubMed ID: 28570668
[TBL] [Abstract][Full Text] [Related]
23. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.
Zhang LM; Zhou JJ; Luo CL
Arthritis Res Ther; 2018 Oct; 20(1):219. PubMed ID: 30285829
[TBL] [Abstract][Full Text] [Related]
24. NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling.
Enesa K; Zakkar M; Chaudhury H; Luong le A; Rawlinson L; Mason JC; Haskard DO; Dean JL; Evans PC
J Biol Chem; 2008 Mar; 283(11):7036-45. PubMed ID: 18178551
[TBL] [Abstract][Full Text] [Related]
25. The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F; Sowa ME; Nalepa G; Gygi SP; Harper JW; Elledge SJ
Proc Natl Acad Sci U S A; 2007 May; 104(21):8869-74. PubMed ID: 17495026
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
27. Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.
Byun JY; Yune TY; Lee JY; Yeo SG; Park MS
Mediators Inflamm; 2010; 2010():796315. PubMed ID: 20414373
[TBL] [Abstract][Full Text] [Related]
28. CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: so similar, yet so different.
Lork M; Verhelst K; Beyaert R
Cell Death Differ; 2017 Jul; 24(7):1172-1183. PubMed ID: 28362430
[TBL] [Abstract][Full Text] [Related]
29. Negative regulation of JNK signaling by the tumor suppressor CYLD.
Reiley W; Zhang M; Sun SC
J Biol Chem; 2004 Dec; 279(53):55161-7. PubMed ID: 15496400
[TBL] [Abstract][Full Text] [Related]
30. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
31. CYLD: a multifunctional deubiquitinase.
Glittenberg M; Ligoxygakis P
Fly (Austin); 2007; 1(6):330-2. PubMed ID: 18820455
[TBL] [Abstract][Full Text] [Related]
32. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.
Takami Y; Nakagami H; Morishita R; Katsuya T; Hayashi H; Mori M; Koriyama H; Baba Y; Yasuda O; Rakugi H; Ogihara T; Kaneda Y
Am J Pathol; 2008 Mar; 172(3):818-29. PubMed ID: 18245814
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
34. Spermidine activates RIP1 deubiquitination to inhibit TNF-α-induced NF-κB/p65 signaling pathway in osteoarthritis.
Chen Z; Lin CX; Song B; Li CC; Qiu JX; Li SX; Lin SP; Luo WQ; Fu Y; Fang GB; Wei-Ping L; Saw PE; Ding Y
Cell Death Dis; 2020 Jul; 11(7):503. PubMed ID: 32632306
[TBL] [Abstract][Full Text] [Related]
35. Prion protein is required for tumor necrosis factor α (TNFα)-triggered nuclear factor κB (NF-κB) signaling and cytokine production.
Wu GR; Mu TC; Gao ZX; Wang J; Sy MS; Li CY
J Biol Chem; 2017 Nov; 292(46):18747-18759. PubMed ID: 28900035
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
Courtois G
Cell Mol Life Sci; 2008 Apr; 65(7-8):1123-32. PubMed ID: 18193168
[TBL] [Abstract][Full Text] [Related]
37. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
[TBL] [Abstract][Full Text] [Related]
38. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
39. Proinflammatory mediators alter expression of nuclear factor kappa B-regulating deubiquitinases in sinonasal epithelial cells.
Li P; Wang Y; Turner JH
Int Forum Allergy Rhinol; 2015 Jul; 5(7):583-9. PubMed ID: 25907801
[TBL] [Abstract][Full Text] [Related]
40. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
Blake PW; Toro JR
Hum Mutat; 2009 Jul; 30(7):1025-36. PubMed ID: 19462465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
